Obesity and weight gain in HIV-infected adults on antiretroviral therapy: What’s the harm?
New Rochelle, NY, February 3, 2016–The percentage of HIV-infected adults who were obese-body mass index >30 kg/m2-when they began antiretroviral therapy (ART) doubled over a 12-year period. After 3 years of ART, 18% of adults who were overweight at initiation of therapy had become obese, and 22% of those with a normal BMI at initiation had become overweight, raising their risk of additional health complications, according to a new study published in AIDS Research and Human Retroviruses, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free to download on the AIDS Research and Human Retroviruses website until March 3, 2016.
John Koethe and coauthors, writing on behalf of the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), present the results of a comparison study of weight gain and BMI for HIV-infected and age-, sex-, and race-matched non-infected adults in North America between 1998 and 2010. The authors report a significantly higher median BMI after 3 years of ART for HIV-infected white women compared to age-matched, non-infected white women (but no significant difference for HIV-infected men or non-white women) in the article "Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada."
"This is an important piece of the puzzle in the ongoing effort to avoid health complications currently seen in aging HIV-infected populations in North America," says Thomas Hope, PhD, Editor-in-Chief of AIDS Research and Human Retroviruses and Professor of Cell and Molecular Biology at Northwestern University, Feinberg School of Medicine (Chicago, IL).
About the Journal
AIDS Research and Human Retroviruses, published monthly online with open access options and in print, presents papers, reviews, and case studies documenting the latest developments and research advances in the molecular biology of HIV and SIV and innovative approaches to HIV vaccine and therapeutic drug research, including the development of antiretroviral agents and immune-restorative therapies. Content also explores the molecular and cellular basis of HIV pathogenesis and HIV/HTLV epidemiology. The Journal features rapid publication of emerging sequence information, reports on clinical trials of emerging HIV therapies, and images in HIV research. Tables of content and a sample issue may be viewed on the AIDS Research and Human Retroviruses website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including AIDS Patient Care and STDs, Viral Immunology, and Journal of Interferon and Cytokine Research. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.